Ionis Pharmaceuticals' CEO Brett Monia discusses the recent trial success of olezarsen in severe hypertriglyceridemia, the approval of Dawnzera in HAE, and more

Sep 8, 2025
1 min read

He describes the significance of the olezarsen trial success in this patient population, and next steps. Plus, how Dawnzera might compete against other medicines in the HAE space, and pipeline programs to watch.

https://vimeo.com/1116881534

Coverage brought to you by:

Recent Posts

See All

Oxford based Infinitopes raised an additional $15.4M in a second closing of its seed round to bring the total raised to $35.1M. It will have clinical data on its cancer vaccine by the end of the year

From Oxford: Carlo Rinaldi's team has received two grants from Oxford-Harrington Rare Disease Centre to develop treatments for Spinal-bulbar muscular atrophy (SBMA) and Friedreich's ataxia

From Oxford: Professor Matthew Wood describes the Oxford-Harrington Rare Disease Centre, a transatlantic effort to accelerate drug development for rare diseases

Ionis Pharmaceuticals' CEO Brett Monia discusses the recent trial success of olezarsen in severe hypertriglyceridemia, the approval of Dawnzera in HAE, and more

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight